Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4KGA

Crystal structure of kallikrein-related peptidase 4

Summary for 4KGA
Entry DOI10.2210/pdb4kga/pdb
Related2bdg 2bdh 2bdi 4K1E 4K8Y 4KEL
DescriptorKallikrein-4, NICKEL (II) ION, 1,2-ETHANEDIOL, ... (4 entities in total)
Functional Keywordsklk4, kallikrein-4, serine protease, protease, hydrolase
Biological sourceHomo sapiens (human)
Cellular locationSecreted: Q9Y5K2
Total number of polymer chains2
Total formula weight48210.93
Authors
Ilyichova, O.V.,Swedberg, J.E.,de Veer, S.J.,Sit, K.C.,Harris, J.M.,Buckle, A.M. (deposition date: 2013-04-29, release date: 2014-04-30, Last modification date: 2023-11-08)
Primary citationRiley, B.T.,Ilyichova, O.,Costa, M.G.S.,Porebski, B.T.,de Veer, S.J.,Swedberg, J.E.,Kass, I.,Harris, J.M.,Hoke, D.E.,Buckle, A.M.
Direct and indirect mechanisms of KLK4 inhibition revealed by structure and dynamics
Sci Rep, 6:35385-35385, 2016
Cited by
PubMed Abstract: The kallikrein-related peptidase (KLK) family of proteases is involved in many aspects of human health and disease. One member of this family, KLK4, has been implicated in cancer development and metastasis. Understanding mechanisms of inactivation are critical to developing selective KLK4 inhibitors. We have determined the X-ray crystal structures of KLK4 in complex with both sunflower trypsin inhibitor-1 (SFTI-1) and a rationally designed SFTI-1 derivative to atomic (~1 Å) resolution, as well as with bound nickel. These structures offer a structural rationalization for the potency and selectivity of these inhibitors, and together with MD simulation and computational analysis, reveal a dynamic pathway between the metal binding exosite and the active site, providing key details of a previously proposed allosteric mode of inhibition. Collectively, this work provides insight into both direct and indirect mechanisms of inhibition for KLK4 that have broad implications for the enzymology of the serine protease superfamily, and may potentially be exploited for the design of therapeutic inhibitors.
PubMed: 27767076
DOI: 10.1038/srep35385
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.32 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon